Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt

Journal of Infectious Diseases

Volumn 200, Issue SUPPL. 1, 2009, Pages

  Ortega, Omayra ^a   El Sayed, Nasr ^c   Sanders, John W ^d   Abd Rabou, Zakaria ^e   Antil, Lynn ^b   Bresee, Joseph ^b   Mansour, Adel ^d   Adib, Ibrahim ^d   Nahkla, Isabelle ^d   Riddle, Mark S ^d  

^a ARIZONA STATE UNIVERSITY WEST   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c MINISTRY OF HEALTH   (Egypt)

^d US Naval Medical Research Unit No 3 Egypt   (Egypt)

^e Abu Homos District Hospital   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIARRHEA; DISABILITY SEVERITY; DRUG COST; EGYPT; GOVERNMENT; HEALTH CARE COST; HOSPITALIZATION; INFECTION RATE; MORTALITY; OUTPATIENT; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SOCIAL ASPECT; VIRUS INFECTION;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; EGYPT; HOSPITALIZATION; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 72849125673     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605057     Document Type: Article

References (25)

1. Widdowson M, Bresee JS, Gentsch JR, Glass RI. Rotavirus disease and its prevention. Curr Opin Gastroenterol 2005; 21:26-31.
2. Reves RR, Hossain MM, Midthun K, et al. An observational study of naturally acquired immunity to rotaviral diarrhea in a cohort of 363 Egyptian children: calculation of risk for second episodes using agespecific person-years of observation. Am J Epidemiol 1989; 130:981-988 (Pubitemid 19285336)
3. Shukry S, Zaki AM, DuPont HL, Shoukry I, el Tagi M, Hamed Z. Detection of enteropathogens in fatal and potentially fatal diarrhea in Cairo, Egypt. J Clin Microbiol 1986; 24:959-962 (Pubitemid 17193348)
4. Cunliffe NA, Kilgore PE, Bresee JS, et al. Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull WHO 1998; 76:525-537
5. Dennehy PH. Rotavirus vaccines: an update. Curr Opin Pediatr 2005; 17:88-92.
6. World Health Organization/United Nations Childrens Fund (UNICEF). Immunization summary 2005: a statistical reference. New York: UNICEF, 2005.
7. Naficy AB, Abu-Elyazeed R, Holmes JL, et al. Epidemiology of rotavirus diarrhea in Egyptian children and implications for disease control. Am J Epidemiol 1999; 150:770-777 (Pubitemid 29463203)
8. Abdel-Messih IA, Wierzba TF, Abu-Elyazeed R, et al. Diarrhea associated with Cryptosporidium parvum among young children of the Nile River Delta in Egypt. J Trop Pediatr 2005; 51:154-159 (Pubitemid 41444460) (Pubitemid 41444460)
9. Murray CJL, Lopez AD; Harvard School of Public Health,World Health Organization, World Bank. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press, 1996.
10. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 2001; 16:326-331 (Pubitemid 32911160)
11. El-Sheikh SM, El-Assouli S. Prevelance of viral, bacterial, and parasitic enteropathogens among young children with acute diarrhoea in Jeddah, Saudi Arabia. J Health Popul Nutr 2001; 19:25-30. (Pubitemid 33688750)
12. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-572
13. Morris SS, Black RE, Tomaskovic L. Predicting the distribution of under-five deaths by cause in countries without adequate vital registration systems. Int J Epidemiol 2003; 32:1041-1051 (Pubitemid 38072693) (Pubitemid 38072693)
14. Bernstein DI, Sack DA, Reisinger K, Rothstein E, Ward RL. Secondyear follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis 2002; 186:1487-1489 (Pubitemid 35286118) (Pubitemid 35286118)
15. Rotavirus vaccine - AVANT immunotherapeutics/GlaxoSmithKline: 89-12, RIX4414. Drugs R D 2004; 5:113-115
16. WHO-ES. Vaccine, immunization, and biologicals: immunization profile. Egypt country profile. 2004. Available at: http://www.emro.who.int/emrinfo/ index.asp?Ctrypegy. Accessed 10 August 2009.
17. Miller P, Hirschhorn N. The effect of a national control of diarrheal diseases program on mortality: the case of Egypt. Soc Sci Med 1995; 40: S1-30.
18. World Health Organization. Egypt country profile. The World Health Report-2004. 2005. Available at: http://www.who.int/whr/2004/annex/country/egy/ en/. Accessed 10 June 2005.
19. Galal O. Nutrition-related health patterns in the Middle East. Asia Pac J Clin Nutr 2003; 12:337-343 (Pubitemid 38880721)
20. Salinas B, Perez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24:807-816 (Pubitemid 41324890) (Pubitemid 41324890)
21. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23:937-943 (Pubitemid 40812781) (Pubitemid 40812781)
22. Waters HR, Dougherty L, Tegang S, et al. Coverage and costs of childhood immunizations in Cameroon. Bull WHO 2004; 82:668-675 (Pubitemid 39278542)
23. Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005; 192(Suppl 1):S133-45.
24. Constenla D, Ortega-Barria E, Rheingans RD, Antil L, Saez-Llorens X. Economic impact of rotavirus vaccination in Panama [in Spanish]. An Pediatr (Barc) 2008; 68:128-135 (Pubitemid 351362788) (Pubitemid 351362788)
25. World Health Organization (WHO). The World Health Report 2002 - reducing risks, promoting health life. Geneva: WHO, 2002:108.